-
Cantor Lifts Aerie's Price Target To $50 Following 'Rock Solid Phase 3 Roclatan Results'
Thursday, September 15, 2016 - 12:11pm | 326Read More...Shares of Aerie Pharmaceuticals Inc (NASDAQ: AERI) soared higher by more than 50 percent Thursday after the company reported Phase 3 data involving Roclatan which met its primary efficacy endpoint. In a report, Dr. Elemer Piros of Cantor Fitzgerald suggested that the data was "impeccable...
-
Good News from Aerie Pharma; Aratana Therapeutics Should Cheer Investors
Thursday, February 18, 2016 - 11:08am | 496Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI) and Aratana Therapeutics Inc (NASDAQ: PETX) have come out with positive announcements that should cheer investors on Thursday. Aerie Pharma reported the successful 12-month interim safety results of Rocket 2, Aerie's second Phase 3 registration trial for...
-
Needham: Aerie Pharma's FDA Agreement 'Re-Establishes A Clinical Path Forward' For Rhopressa
Tuesday, June 16, 2015 - 11:55am | 383Read More...Aerie Pharmaceuticals Inc (NASDAQ: AERI) has created a lot of buzz this morning as shares jumped 56 percent in pre-market trading following news that the FDA has allowed the company to modify the primary endpoint of its second Phase 3 trial of Rhopressa; an eye drop that alleviates intraocular...
